Tradegate
02.02.26 | 08:25
4,040 Euro
-0,49 % -0,020
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,000 | 4,100 | 12:27 | |
| 4,000 | 4,100 | 11:03 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.01. | H.C. Wainwright bestätigt "Buy"-Rating für Silence Therapeutics mit Kursziel von 75 $ | 10 | Investing.com Deutsch | ||
| 23.01. | H.C. Wainwright reiterates Buy rating on Silence Therapeutics stock at $75 | 2 | Investing.com | ||
| 22.12.25 | Silence Therapeutics beruft CFO Rhonda Hellums in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 15.12.25 | Silence Therapeutics plc - 8-K, Current Report | 1 | SEC Filings | ||
| 15.12.25 | Silence Therapeutics Announces Leadership Changes | 1 | City A.M. | ||
| 15.12.25 | Silence Therapeutics CEO Craig Tooman steps down | 1 | Investing.com | ||
| 15.12.25 | Silence Therapeutics CEO Tooman to depart; Chairman Ross to lead on interim basis | 4 | Seeking Alpha | ||
| 12.11.25 | Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference | 6 | City A.M. | ||
| SILENCE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | Silence Therapeutics plc: Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference | 366 | Business Wire | Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in a fireside chat... ► Artikel lesen | |
| 06.11.25 | Silence Therapeutics: EPS übertrifft Schätzungen um 0,04 $ - Umsatz schlechter als erwartet | 7 | Investing.com Deutsch | ||
| 06.11.25 | Silence Therapeutics plc Non-GAAP EPS of -$0.15, revenue of $0.16M | 2 | Seeking Alpha | ||
| 06.11.25 | Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 5 | City A.M. | ||
| 06.11.25 | Silence Therapeutics plc: Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 447 | Business Wire | SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026 Strong balance sheet and cash runway into 2028
Silence Therapeutics plc, Nasdaq:... ► Artikel lesen | |
| 06.11.25 | Silence Therapeutics plc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.11.25 | Silence Therapeutics plc - 8-K, Current Report | 2 | SEC Filings | ||
| 23.10.25 | Silence Therapeutics plc - 8-K, Current Report | 5 | SEC Filings | ||
| 23.10.25 | Silence Therapeutics completes enrollment in PV treatment study | 5 | Investing.com | ||
| 23.10.25 | Silence Therapeutics plc: Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) | 360 | Business Wire | Rapid Completion of Phase 2 Enrollment Reflects Ongoing Momentum for Divesiran as First-in-Class siRNA for PV Topline Results Anticipated in 3Q'26
Silence Therapeutics plc (Nasdaq: SLN), a global... ► Artikel lesen | |
| 02.09.25 | Silence Therapeutics plc: Silence Therapeutics to Participate in September Investor Conferences | 441 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate... ► Artikel lesen | |
| 07.08.25 | Silence Therapeutics plc - 10-Q, Quarterly Report | 3 | SEC Filings |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 48,910 | -2,32 % | Novo Nordisk: Spannende Comeback-Story | Novo Nordisk wurde in den vergangenen Monaten vom Markt brutal abgestraft. Von über 1.000 Dänische Kronen Mitte 2024 ging es bei dem Papier bis November vergangenen Jahres zeitweise bis unter 300 Kronen... ► Artikel lesen | |
| GILEAD SCIENCES | 119,72 | -0,07 % | Leerink Partners raises Gilead Sciences stock price target to $146 on HIV pipeline | ||
| VERTEX PHARMACEUTICALS | 395,50 | -0,26 % | Prediction: 2026 Will Be the Year of Vertex Pharmaceuticals | ||
| INNOCAN PHARMA | 5,700 | +3,64 % | Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering | HERZLIYA, Israel and CALGARY, AB, Jan. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 70,00 | +0,37 % | EU Approves DAWNZERA For Hereditary Angioedema, Says Ionis And Otsuka | TOKYO (dpa-AFX) - Ionis Pharmaceuticals, Inc. (IONS) and Otsuka Pharmaceutical Co., Ltd. on Wednesday said the European Commission has approved Dawnzera to prevent repeated attacks of hereditary... ► Artikel lesen | |
| SNDL | 1,310 | +0,46 % | SNDL Inc. (SNDL) Completes Initial 1CM Retail Acquisition, Expands Footprint Across Western Canada | ||
| ASSEMBLY BIOSCIENCES | 22,100 | +1,38 % | Gilead Exercises Option To License Assembly Bio's Helicase-Primase Inhibitor Programs | FOSTER CITY (dpa-AFX) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 1,080 | -1,82 % | Happy Belly Food Group Inc.: Happy Belly's Yolks Breakfast Signs Franchise Agreement and Real-Estate Location in the City of Langley, British Columbia | Toronto, Ontario--(Newsfile Corp. - January 26, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFG) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 286,30 | +0,42 % | Should You Buy Alnylam Pharmaceuticals Before Feb. 12? | ||
| LIGAND PHARMACEUTICALS | 160,00 | -1,23 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 3,620 | +2,40 % | Achieve Life Sciences Announced Granting of New Hire Inducement Awards | ||
| PROMINO NUTRITIONAL SCIENCES | 0,010 | 0,00 % | Promino Nutritional Sciences, Inc.: Promino Announces Closing of Private Placement | Burlington, Ontario--(Newsfile Corp. - January 30, 2026) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FSE: 93X) ("Promino" or the "Company") is pleased to announce that, further... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 10,800 | -0,92 % | Neuer Geheimtipp aus der Biotech-Szene - Wave Life Sciences hat sich zu Wochenbeginn mehr als verdoppelt! | Ist ein neuer Abnehm-Star geboren? Wave Life Sciences könnte mit einem bisher einzigartigen Wirkstoff den Adipositas-Markt aufmischen. Ein Ansatz, der Fett abbaut, Muskeln erhält und die Konkurrenz... ► Artikel lesen | |
| DARE BIOSCIENCE | 1,810 | 0,00 % | Dare Bioscience, Inc. - 8-K, Current Report | ||
| HYTN INNOVATIONS | 0,176 | -0,56 % | HYTN begrüßt US-Präsidialverordnung zur Einstufung von Cannabis in Schedule III | Vancouver, British Columbia - 18. Dezember 2025 / IRW-Press / HYTN Innovations Inc. (CSE: HYTN, FWB: 85W0, OTC PINK: HYTNF) ("HYTN" oder das "Unternehmen"), ein
Hersteller von Cannabis in pharmazeutischer... ► Artikel lesen |
Das Unternehmen SILENCE THERAPEUTICS PLC ADR kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,49 % bei einem Aktienkurs von 4,040 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILENCE THERAPEUTICS PLC ADR finden Sie auf Wallstreet Online.